Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
14 7월 2023 - 12:15PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
the pricing of an upsized underwritten public offering of
19,230,769 shares of its common stock at a public offering price of
$6.50 per share. All of the common stock to be sold in the offering
will be offered by Caribou. The gross proceeds to Caribou from the
offering, before deducting underwriting discounts and commissions
and offering expenses, are expected to be approximately $125
million, excluding any exercise of the underwriters’ option.
Caribou has granted the underwriters a 30-day option to purchase up
to an additional 2,884,615 shares of its common stock at the public
offering price per share, less underwriting discounts and
commissions.
The offering is expected to close on or about July 18, 2023,
subject to satisfaction of customary closing conditions.
BofA Securities, Leerink Partners, Evercore ISI, and RBC Capital
Markets are acting as book-running managers for the proposed
offering.
The securities are being offered by Caribou pursuant to an
effective shelf registration statement on Form S-3 that was
previously filed with the U.S. Securities and Exchange Commission
(SEC) on August 9, 2022. A preliminary prospectus supplement and
accompanying prospectus relating to and describing the terms of the
offering has been filed with the SEC and is available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and accompanying prospectus relating to the proposed public
offering may be obtained, when available, from: BofA Securities,
NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001,
Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; Leerink Partners, 53 State Street,
40th Floor, Boston, MA 02109, or by email at syndicate@leerink.com;
Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd
Street, 35th Floor, New York, NY 10055, by telephone at (888)
474-0200 or by email at ecm.prospectus@evercore.com; RBC Capital
Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street,
8th Floor, New York, NY, 10281, or by telephone at (877) 822-4089
or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its Cas12a chRDNA
technology, enables superior precision to develop cell therapies
that are armored to potentially improve antitumor activity. Caribou
is advancing a pipeline of off-the-shelf cell therapies from its
CAR-T and CAR-NK platforms as readily available treatments for
patients with hematologic malignancies and solid tumors.
Forward-looking statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation,
statements related to Caribou’s expectations with respect to the
size, completion and timing of the closing of the offering. No
assurance can be given that the offering discussed above will be
completed on the terms or timing described in this release or at
all. Management believes that these forward-looking statements are
reasonable as and when made. However, such forward-looking
statements are subject to risks and uncertainties, and actual
results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties
include, without limitation, changes in market conditions and the
satisfaction of customary closing conditions, as well as other risk
factors described from time to time in Caribou’s filings with the
SEC, including its Annual Report on Form 10-K for the year ended
December 31, 2022, and subsequent filings. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. Except as required by law, Caribou undertakes no
obligation to update publicly any forward-looking statements for
any reason.
Caribou Biosciences, Inc.
contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald,
PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Caribou Biosciences (NASDAQ:CRBU)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024